Atezolizumab-Induced Bell’s Palsy in a Patient With Small Cell Lung Cancer

Immune checkpoint inhibitors are rapidly becoming popular therapeutic options for patients suffering from a number of malignancies. Atezolizumab is a programmed cell death ligand-1 inhibitor, and binding to this ligand decreases the ability of tumor cells to evade the immune system, resulting in sel...

Descripción completa

Detalles Bibliográficos
Autores principales: Kichloo, Asim, Albosta, Michael Stanley, Jamal, Shakeel M., Aljadah, Michael, Wani, Farah, Selene, Insija, Singh, Jagmeet, Taj, Asma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557644/
https://www.ncbi.nlm.nih.gov/pubmed/33047629
http://dx.doi.org/10.1177/2324709620965010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557644/
https://www.ncbi.nlm.nih.gov/pubmed/33047629
http://dx.doi.org/10.1177/2324709620965010

Ejemplares similares